" class="no-js "lang="en-US"> James Nolan - Medtech Alert
Wednesday, March 27, 2024
James Nolan

James Nolan

About James Nolan

James M. Nolan actively explores and identifies business opportunities and novel technologies to establish and promote new life science products and companies. Jim is the CEO of IPD llc in Guilford Ct. and the Operating Partner of Velocity Fund Partners in Pittsburgh, Pa. Jim is involved in the formation and management of SkinJect, Periovance, Signalence, InClinica and DermalBiomics. Jim has and is providing consulting services to University of Pittsburgh, Allegheny Health Network, Mars Inc., Alms Therapeutics, CytoAgents and several other organizations. He is a founder, President and Chief Executive Officer of the Institutes for Pharmaceutical Discovery. L.L.C. (IPD), based in Branford, Connecticut. IPD consists of three institutes: the Institute for Drug Discovery, L.L.C., (IDD), the Institute for Bioanalytics, L.L.C. (IBA), and IPD Consumer Health, L.L.C. and provides major consulting services for a number of clients in the Life Science Industry. Mr. Nolan began his pharmaceutical career at Merrill Dow Pharmaceuticals. The pharmaceutical arm of Dow Chemical. During his career at Merrill-Dow and Ohmeda PPD, he participated in the development of corporate strategies and product positioning for allergy, AIDS, gastrointestinal, anti-infective, and anesthesia products. His major role at Dow was as an interface between R&D and the business organization. At Wyeth-Ayerst, Mr. Nolan served as the Chairman of the Research and Development Task Force. His responsibilities included strategic planning for domestic and international new product introductions, as well as research development and marketing management, with a focus on new product discovery research / business rollout and acquisition in the Pharmeceutical and Consumer Product areas. As President / CEO, in late 1995, Mr. Nolan established IPD to discover and promote novel therapies for diabetic complications, diabetes, obesity, and related disorders. This focus grew to include inflammation, pain, cardiovascular disease, dermatology and cancer. IPD employed research scientists having expertise in synthetic medicinal chemistry, in vitro screening, pharmacology, pharmacokinetics, and in vivo modeling. In 1998, Mr. Nolan organized IBA, which developed customized single-plexed and multiplexed assays for the pharmaceutical and diagnostic/device industries. IPD Consumer Health was established in 2004 and provided specific, business development, targeted markeing and sales initiatives for global niche markets with solid scientific support. He is a graduate of Villanova University and completed the Executive Progam in Marketing Management at the University of Michigan.

Related Story

Adipopharma’s First-in-class Candidate - PATAS - Shows Improvement in Whole-body Insulin Resistance and Associated Comorbidities in Vivo

July 15 2022

AdipoPharma, formerly ALMS Therapeutics SAS, a biopharmaceutical company focused on innovative peptide-based approaches to treating […]